# RNN 1st Gen Model Celgene Corporation Pharmaceutical preparations
at 18-dec-2018
CELG
Model's trade recommendations 2.98% Return for period
12.51% Annual return
$63.12B Market Cap
β 1.49
CELG
Model (following trade recommendations)CELG
Underlying stockS&P 500
Index- BUY Analysts consensus recommendation
Celgene Corporation is a global biopharmaceutical company engaged in the discovery, development and commercialization of innovative therapies for the treatment of cancer and immune-inflammatory related diseases. Their portfolio of commercial products include REVLIMID, VIDAZA, THALOMID, POMALYST/IMNOVID, ABRAXANE, OTEZLA, ISTODAX and IDHIFA. The drug candidates in their pipeline are at various stages of preclinical and clinical development. These candidates include their IMiDs compounds, which are a proprietary class of compounds that have certain immunomodulatory and other biologically important properties in addition to their leading oral anti-inflammatory agents and cellular therapies. They believe their commercial stage products and the depth of their product pipeline, provide the catalysts for future growth.
Industry sector: Medical
Sector classification: Pharmaceutical preparations
Deep Learning based analysis and prediction model for Celgene Corporation (CELG) stock is a 1st Generation Non-linear Autoregresive with exogenous variable(s) (NARX) model based on the Recurrent Neural Network architecture.
Model is in the production pipeline since Oct. 2, 2015.
Market data for CELG model training are being downloaded from the Quandl premium datasets on a daily basis.
Model is being retrained on a daily basis.
| Float | 719M |
| P/E | 12.67 |
| Shares Outstanding | 726M |
| % Held by Insiders | 0.95% |
| % Held by Institutions | 78.42% |
| EPS (last reported FY) | $6.84 |
| EPS (last reported Q) | $1.87 |
| EPS, estimated (last reported Q) | $1.78 |
| Total revenues | $13 B |
| Net income | $3 B |